How big is Azenta, Inc.?

As of Jun 18, Azenta, Inc. has a market capitalization of 1,736.38 million, with net sales of 633.80 million and a net profit of -39.16 million over the latest four quarters. The company reported shareholder's funds of 1,768.97 million and total assets of 2,100.04 million as of Sep 24.

Market Cap: As of Jun 18, Azenta, Inc. has a market capitalization of 1,736.38 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Azenta, Inc. reported net sales of 633.80 million and a net profit of -39.16 million.<BR><BR>Balance Sheet Snapshot: As of Sep 24, the company reported shareholder's funds of 1,768.97 million and total assets of 2,100.04 million.

What does Azenta, Inc. do?

Azenta, Inc. provides automation solutions for the Pharmaceuticals & Biotechnology industry, with recent net sales of $143 million and a net loss of $18 million. The company has a market cap of $1.74 billion and does not pay dividends.

Overview:<BR>Azenta, Inc. is a provider of automation solutions in the Pharmaceuticals & Biotechnology industry, operating within the small-cap market segment.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 143 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -18 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 1,736.38 Million (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.19<BR>- Return on Equity: -1.39%<BR>- Price to Book: 1.02<BR><BR>Contact Details:<BR>- Address: 15 Elizabeth Dr, CHELMSFORD MA: 01824-4111<BR>- Tel: ['1 978 2622400', '1 978 2622635']<BR>- Fax: 1 978 2622500<BR>- Website: https://www.brooks.com/

Should I buy, sell or hold Azenta, Inc.?

Who are in the management team of Azenta, Inc.?

As of March 2022, the management team of Azenta, Inc. includes Dr. Joseph Martin (Independent Chairman), Dr. Stephen Schwartz (President and CEO), and five Independent Directors: Ms. Robyn Davis, Ms. Erica McLaughlin, Prof. Dr. Krishna Palepu, and Mr. Kirk Pond.

As of March 2022, the management team of Azenta, Inc. includes the following individuals:<BR><BR>- Dr. Joseph Martin, who serves as the Independent Chairman of the Board.<BR>- Dr. Stephen Schwartz, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Robyn Davis, who is an Independent Director.<BR>- Ms. Erica McLaughlin, who is also an Independent Director.<BR>- Prof. Dr. Krishna Palepu, serving as an Independent Director.<BR>- Mr. Kirk Pond, who is another Independent Director. <BR><BR>This team comprises a mix of executive leadership and independent directors.

Is Azenta, Inc. technically bullish or bearish?

As of October 10, 2025, Azenta, Inc. is in a bearish trend with weak strength indicators, underperforming the S&P 500 significantly with a year-to-date return of -38.96% compared to the S&P's 11.41%.

As of 10 October 2025, the technical trend for Azenta, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a weak strength indicated by the daily moving averages and the weekly KST. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly, suggesting mixed signals across different periods. The Bollinger Bands and Dow Theory also indicate bearish conditions. <BR><BR>In terms of performance, Azenta has underperformed the S&P 500 significantly over multiple periods, with a year-to-date return of -38.96% compared to the S&P 500's 11.41%, and a 5-year return of -41.80% versus 88.45% for the benchmark.

Is Azenta, Inc. overvalued or undervalued?

As of November 21, 2025, Azenta, Inc. has improved to an attractive valuation grade but appears overvalued with a high EV to EBITDA of 38.38 and negative ROCE of -2.84%, underperforming the S&P 500 and its peers.

As of 21 November 2025, the valuation grade for Azenta, Inc. has moved from risky to attractive, indicating a significant improvement in its perceived value. Despite this positive shift, the company appears to be overvalued based on its current financial metrics. The Price to Book Value stands at 1.00, while the EV to EBITDA is notably high at 38.38, suggesting that investors are paying a premium relative to earnings before interest, taxes, depreciation, and amortization. Additionally, the ROCE is negative at -2.84%, reflecting inefficiencies in generating returns from capital employed.<BR><BR>In comparison to its peers, Azenta's valuation metrics are concerning; for instance, Encompass Health Corp. has a more favorable EV to EBITDA of 12.89, while The Ensign Group, Inc. shows a P/E ratio of 32.46, indicating better market positioning. Furthermore, Azenta's stock has underperformed relative to the S&P 500 over multiple periods, with a year-to-date return of -26.60% compared to the S&P 500's 12.26%. This underperformance reinforces the notion that Azenta may be overvalued in the current market context.